Show simple item record

dc.contributor.authorStahel, R
dc.contributor.authorThatcher, Nick
dc.contributor.authorFrüh, M
dc.contributor.authorLe Péchoux, C
dc.contributor.authorPostmus, P E
dc.contributor.authorSorensen, J B
dc.contributor.authorFelip, E
dc.contributor.authorFaivre-Finn, Corinne
dc.contributor.authorBlackhall, Fiona H
dc.date.accessioned2012-05-28T11:50:23Z
dc.date.available2012-05-28T11:50:23Z
dc.date.issued2011-09
dc.identifier.citation1st ESMO Consensus Conference in lung cancer; Lugano 2010: small-cell lung cancer. 2011, 22 (9):1973-80 Ann Oncolen_GB
dc.identifier.issn1569-8041
dc.identifier.pmid21727198
dc.identifier.doi10.1093/annonc/mdr313
dc.identifier.urihttp://hdl.handle.net/10541/226232
dc.description.abstractThe 1st ESMO Consensus Conference on lung cancer was held in Lugano, Switzerland on 21st and 22nd May 2010 with the participation of a multidisciplinary panel of leading professionals in pathology and molecular diagnostics and medical, surgical and radiation oncology. Before the conference, the expert panel prepared clinically relevant questions concerning five areas as follows: early and locally advanced non-small-cell lung cancer (NSCLC), first-line metastatic NSCLC, second-/third-line NSCLC, NSCLC pathology and molecular testing, and small-cell lung cancer (SCLC) to be addressed through discussion at the Consensus Conference. All relevant scientific literature for each question was reviewed in advance. During the Consensus Conference, the panel developed recommendations for each specific question. The consensus agreement in SCLC is reported in this article. The recommendations detailed here are based on an expert consensus after careful review of published data. All participants have approved this final update.
dc.language.isoenen
dc.rightsArchived with thanks to Annals of oncology : official journal of the European Society for Medical Oncology / ESMOen_GB
dc.subject.meshCarcinoma, Small Cell
dc.subject.meshHumans
dc.subject.meshLung Neoplasms
dc.subject.meshNeoplasm Staging
dc.title1st ESMO Consensus Conference in lung cancer; Lugano 2010: small-cell lung cancer.en
dc.typeArticleen
dc.contributor.departmentDepartment of Oncology, University Hospital Zurich, Zurich, Switzerland.en_GB
dc.identifier.journalAnnals of Oncologyen_GB
html.description.abstractThe 1st ESMO Consensus Conference on lung cancer was held in Lugano, Switzerland on 21st and 22nd May 2010 with the participation of a multidisciplinary panel of leading professionals in pathology and molecular diagnostics and medical, surgical and radiation oncology. Before the conference, the expert panel prepared clinically relevant questions concerning five areas as follows: early and locally advanced non-small-cell lung cancer (NSCLC), first-line metastatic NSCLC, second-/third-line NSCLC, NSCLC pathology and molecular testing, and small-cell lung cancer (SCLC) to be addressed through discussion at the Consensus Conference. All relevant scientific literature for each question was reviewed in advance. During the Consensus Conference, the panel developed recommendations for each specific question. The consensus agreement in SCLC is reported in this article. The recommendations detailed here are based on an expert consensus after careful review of published data. All participants have approved this final update.


This item appears in the following Collection(s)

Show simple item record